Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer
Barfeld, Stefan J; Fazli, Ladan; Persson, Margareta; Marjavaara, Lisette; Urbanucci, Alfonso; Kaukoniemi, Kirsi; Rennie, Paul S; Ceder, Yvonne; Chables, Andrei; Visakorpi, Tapio; Mills, Ian G (2015)
Barfeld, Stefan J
Fazli, Ladan
Persson, Margareta
Marjavaara, Lisette
Urbanucci, Alfonso
Kaukoniemi, Kirsi
Rennie, Paul S
Ceder, Yvonne
Chables, Andrei
Visakorpi, Tapio
Mills, Ian G
2015
Oncotarget 6 14
12587-12602
BioMediTech - BioMediTech
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:uta-201609072243
https://urn.fi/URN:NBN:fi:uta-201609072243
Kuvaus
This article has supplementary files, which can be found here: http://dx.doi.org/10.18632/oncotarget.3494
Tiivistelmä
The androgen receptor is a key transcription factor contributing to the development of all stages of prostate cancer (PCa). In addition, other transcription factors have been associated with poor prognosis in PCa, amongst which c-Myc (MYC) is a well-established oncogene in many other cancers. We have previously reported that the AR promotes glycolysis and anabolic metabolism; many of these metabolic pathways are also MYC-regulated in other cancers. In this study, we report that in PCa cells de novo purine biosynthesis and the subsequent conversion to XMP is tightly regulated by MYC and independent of AR activity. We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA). Treatment with MPA led to a significant reduction in cellular guanosine triphosphate (GTP) levels accompanied by nucleolar stress and p53 stabilization. In conclusion, targeting purine biosynthesis provides an opportunity to perturb PCa metabolism and enhance tumour suppressive stress responses.
Kokoelmat
- Artikkelit [6140]